IC 265 is being developed for the treatment of dry eye

Dry eye disease (DED) is a chronic inflammatory condition affecting 334 million people worldwide.

IC 265 is being developed with the ability to significantly improve both the safety and efficacy of existing DED therapies.

In a Phase 2 conjunctival allergy challenge study, IC 265 demonstrated the following:

Fast acting

Takes 1 to 4 hours to reduce physiological responses

Well tolerated

Had no adverse effects reported relating to discomfort

Reduced redness

Was effective in reducing redness when dosed 8 hours prior to administration of allergy challenge

Reduced inflammation

Was effective in reducing inflammation demonstrated by confocal microscopy

IPAC’s R&D in action

IC 265 uses our SYK kinase inhibitor that is able to block multiple downstream signaling pathways leading to different ophthalmic ailments, including dry eye.

Learn more about SYK kinase inhibitors

IC 265: Development strategy

Scientific and clinical validation

  • Completed Phase 2 in Conjunctival Allergen Challenge (CAC) model as proof of concept (POC) for ocular surface inflammation

  • Positive POC for ocular surface activity in reducing redness and demonstrated anti-inflammatory effect

  • IC 265 concentrations were found well tolerated in the Phase 2 study

Formulation

  • Manufacturing clinical supplies for Good Manufacturing Practice (GMP)

Clinical Development

  • Open Investigational New Drug (IND) application with US FDA

  • Planned Phase 2 parallel-group study in dry eye patients

View other products

IC 270

for allergic conjunctivitis

Learn more

IC 800

for acute pain relating to ocular post-surgical pain management

Learn more

IC 805

for chronic pain relating to ocular post-surgical pain management

Learn more